Sales and earnings by business segment

In 2021, we expect sales and earnings development in our business segments as shown in the table.

Download (XLSX, 37 KB)
Financial targets by business segment 2021
Targets 20211 Fiscal year 20202
Fresenius Medical Care3
Sales growth (in constant currency) Low-to-mid single-digit percentage growth € 17,859 m
Net income4 growth (in constant currency) High-teens to mid-twenties percentage decline € 1,359 m
Fresenius Kabi
Sales growth (organic) Low-to-mid single-digit percentage growth € 6,976 m
EBIT growth (in constant currency) Stable to low single-digit percentage growth € 1,095 m
Fresenius Helios
Sales growth (organic) Low-to-mid single-digit percentage growth € 9,818 m
EBIT growth (in constant currency) Mid-to-high single-digit percentage growth € 1,025 m
Fresenius Vamed
Sales growth (organic) Mid-to-high single-digit percentage growth € 2,068 m
EBIT High double-digit € million amount € 29 m
1 Before special items, including expected COVID-19 effects
2 Before special items, including COVID-19 effects 
3 These targets are based on the 2020 results excluding the impairment of goodwill and trade names in the Latin America Segment of € 195 million. They are inclusive of anticipated COVID-19 effects, in constant currency and exclude special items. Special items include costs related to cost-saving measures and other effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of giving guidance. 
4 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-2294
pr-fre@fresenius.com

Visit us

Fresenius SE & Co. KGaA

Group sales and earnings

Expenses